Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Hold” from Analysts

Progyny, Inc. (NASDAQ:PGNY) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $25.83.

PGNY has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Barclays decreased their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Truist Financial reaffirmed a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Bank of America boosted their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th.

Progyny Trading Down 0.5 %

NASDAQ:PGNY opened at $22.88 on Friday. Progyny has a 1-year low of $13.39 and a 1-year high of $38.98. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 2.39 and a beta of 1.34. The business’s 50-day moving average price is $20.52 and its two-hundred day moving average price is $18.68.

Insider Activity

In related news, CEO Peter Anevski purchased 209,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman David J. Schlanger acquired 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PGNY. Voya Investment Management LLC grew its stake in shares of Progyny by 1.4% in the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock valued at $893,000 after acquiring an additional 701 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after purchasing an additional 1,246 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after buying an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares in the last quarter. Finally, KBC Group NV grew its position in Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.